Open AccessYet another utility for isocitrate dehydrogenase.1: Can it serve as an immunomarker to assess tumor margins in gliomas?
Author(s) -
Shaline Rao,
Aarthi Rajkumar,
Sandhya Sundaram,
Mintu Elizabeth Joyce,
D Prathiba
Publication year - 2020
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/jcrt.jcrt_22_17
Subject(s) - isocitrate dehydrogenase , idh1 , gliosis , immunostaining , pathology , glioma , immunohistochemistry , parenchyma , oligodendroglioma , medicine , brain tumor , biology , astrocytoma , cancer research , mutation , biochemistry , gene , enzyme
Isocitrate dehydrogenase-1 (IDH1) mutation is now an established early event in gliomagenesis. The ability to detect this mutation by several techniques including immunohistochemistry makes it a significant marker for diagnosing and prognosticating gliomas. This study was done to assess the expression of mutant IDH1 in different grades of gliomas and evaluate its utility in differentiating reactive gliosis from glioma and defining surgical margins of these tumors in the operative specimens.